Mechanisms that regulate erythroid differentiation of hematopoietic stem cells

造血干细胞红系分化的调节机制

基本信息

  • 批准号:
    10647781
  • 负责人:
  • 金额:
    $ 58.21万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-07-01 至 2026-06-30
  • 项目状态:
    未结题

项目摘要

Hematopoietic stem cells (HSCs) are capable of regenerating the entire hematopoietic system. This capacity is fully unleashed upon bone marrow transplantation, however, recent studies including ours indicate that HSCs have a much more limited contribution to hematopoiesis during homeostasis. While stress from sources like chemotherapies or inflammation increases the contribution from HSCs to multiple hematopoietic lineages, little is known about how HSCs respond to stressors that cause anemia. Identifying the progenitor cell population and signals that promote erythroid regeneration may lead to novel strategies to better harness HSCs for the treatment of anemia and regenerative medicine overall. Using a HSC lineage tracing model, we found that hemolytic anemia specifically enhances erythroid contribution by HSCs, indicating that HSCs respond to erythroid stress by initiating erythropoiesis. After hemolytic anemia, HSCs expressed more erythropoiesis-related genes and exhibited enhanced erythroid differentiation in vitro and in vivo. Interestingly, HSCs had increased iron content after hemolytic anemia and iron chelation prevented erythroid-biased differentiation. Iron is a cofactor for the iron(II)/α-ketoglutarate-dependent dioxygenase TET2 that demethylates DNA, and erythropoiesis is associated with DNA demethylation. We found that TET2 protein, but not mRNA, is increased in HSCs during anemia and deletion of Tet2 suppressed the enhanced erythroid differentiation of HSCs we observed following hemolytic anemia. We thus hypothesized that HSCs respond to anemia by increasing iron uptake, TET2 expression, and DNA demethylation, thereby increasing the expression of erythropoiesis genes. In Aim 1, we will study the heterogeneity of splenic HSCs during anemia and identify the erythroid-biased fraction of HSCs. In Aim 2, we will examine the role of TET2 in promoting erythroid commitment of splenic HSC. In Aim 3, we will investigate the mechanism by which TET2 protein is stabilized in HSCs during anemia. Completion of this study will provide novel insights into the differences between bone marrow and splenic HSCs in responding to anemia, and the mechanism by which iron and TET2 instructs HSCs to become committed to the erythroid lineage.
造血干细胞(HSC)能够再生整个造血系统。这种能力是 然而,包括我们在内的最近的研究表明,造血干细胞在骨髓移植后完全释放, 在体内平衡过程中对造血的贡献要有限得多。当压力来自于 化疗或炎症增加了HSC对多种造血谱系的贡献, 关于造血干细胞如何对导致贫血的应激源做出反应的研究已经被人们所知。鉴定祖细胞群体, 促进红细胞再生的信号可能会导致更好地利用HSC进行治疗的新策略 贫血和再生医学的发展使用HSC谱系追踪模型,我们发现, 贫血特异性地增强HSC对红系细胞的贡献,表明HSC对红系细胞应激有反应 通过启动红细胞生成溶血性贫血后,HSC表达更多的红细胞生成相关基因, 在体外和体内表现出增强的红系分化。有趣的是,HSC铁含量增加, 在溶血性贫血和铁螯合阻止红细胞偏向分化之后。铁是一种辅助因子, 铁(II)/α-酮戊二酸依赖性双加氧酶TET 2,可使DNA去甲基化,与红细胞生成相关 DNA去甲基化我们发现,TET 2蛋白,而不是mRNA,在造血干细胞在贫血, Tet 2的缺失抑制了我们观察到的溶血性造血干细胞的红系分化增强, 贫血因此,我们假设造血干细胞通过增加铁摄取、TET 2表达和 DNA去甲基化,从而增加红细胞生成基因的表达。在目标1中,我们将研究 在贫血期间观察脾HSC的异质性,并鉴定HSC的红系偏向部分。在目标2中, 将研究TET 2在促进脾HSC红系定型中的作用。在目标3中,我们将研究 TET 2蛋白在贫血期间在HSC中稳定的机制。本研究的完成将提供 新的见解骨髓和脾造血干细胞之间的差异,在响应贫血, 铁和TET 2指导HSC定型为红系细胞的机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Daisuke Nakada其他文献

Daisuke Nakada的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Daisuke Nakada', 18)}}的其他基金

Project 2: The role of the DNA damage response in clonal competition following genotoxic stress
项目 2:DNA 损伤反应在基因毒性应激后克隆竞争中的作用
  • 批准号:
    10332336
  • 财政年份:
    2022
  • 资助金额:
    $ 58.21万
  • 项目类别:
Mechanisms that regulate erythroid differentiation of hematopoietic stem cells
造血干细胞红系分化的调节机制
  • 批准号:
    10509652
  • 财政年份:
    2022
  • 资助金额:
    $ 58.21万
  • 项目类别:
Project 2: The role of the DNA damage response in clonal competition following genotoxic stress
项目 2:DNA 损伤反应在基因毒性应激后克隆竞争中的作用
  • 批准号:
    10606554
  • 财政年份:
    2022
  • 资助金额:
    $ 58.21万
  • 项目类别:
THE ROLE OF SELENOPROTEIN SYNTHESIS PATHWAY IN ACUTE MYELOID LEUKEMIA
硒蛋白合成途径在急性髓系白血病中的作用
  • 批准号:
    10659193
  • 财政年份:
    2021
  • 资助金额:
    $ 58.21万
  • 项目类别:
THE ROLE OF SELENOPROTEIN SYNTHESIS PATHWAY IN ACUTE MYELOID LEUKEMIA
硒蛋白合成途径在急性髓系白血病中的作用
  • 批准号:
    10434125
  • 财政年份:
    2021
  • 资助金额:
    $ 58.21万
  • 项目类别:
THE ROLE OF SELENOPROTEIN SYNTHESIS PATHWAY IN ACUTE MYELOID LEUKEMIA
硒蛋白合成途径在急性髓系白血病中的作用
  • 批准号:
    10296885
  • 财政年份:
    2021
  • 资助金额:
    $ 58.21万
  • 项目类别:
Mesenchymal Stromal Cells Regulate Hematopoietic Stem Cell Aging
间充质基质细胞调节造血干细胞衰老
  • 批准号:
    9404451
  • 财政年份:
    2016
  • 资助金额:
    $ 58.21万
  • 项目类别:
Mesenchymal Stromal Cells Regulate Hematopoietic Stem Cell Aging
间充质基质细胞调节造血干细胞衰老
  • 批准号:
    9189715
  • 财政年份:
    2016
  • 资助金额:
    $ 58.21万
  • 项目类别:
Metabolic Regulation in Leukemia-Initatiating Cells
白血病起始细胞的代谢调节
  • 批准号:
    9245651
  • 财政年份:
    2015
  • 资助金额:
    $ 58.21万
  • 项目类别:
Metabolic Regulation in Leukemia-Initatiating Cells
白血病起始细胞的代谢调节
  • 批准号:
    9017971
  • 财政年份:
    2015
  • 资助金额:
    $ 58.21万
  • 项目类别:

相似国自然基金

基于构建骨骼类器官模型探究Fanconi anemia信号通路调控电刺激诱导神经化成骨过程的机制研究
  • 批准号:
    82302715
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
FANCM蛋白在传统Fanconi anemia通路以外对保护基因组稳定性的功能
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
范可尼贫血(Fanconi Anemia)基因FANCM在复制后修复中的作用及FA癌症抑制通路的机制研究
  • 批准号:
    31200592
  • 批准年份:
    2012
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Investigation of crosstalk between Fanconi Anemia pathway and ATM for novel therapeutic strategies of chemoresistant ALT-positive high-risk neuroblastoma
范可尼贫血通路与 ATM 之间的串扰研究,用于化疗耐药 ALT 阳性高危神经母细胞瘤的新治疗策略
  • 批准号:
    24K10442
  • 财政年份:
    2024
  • 资助金额:
    $ 58.21万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Immune escape mechanisms in BCOR/BCORL1 mutant hematopoietic stem cells from patients with aplastic anemia
再生障碍性贫血患者 BCOR/BCORL1 突变型造血干细胞的免疫逃逸机制
  • 批准号:
    23K15297
  • 财政年份:
    2023
  • 资助金额:
    $ 58.21万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Fanconi anemia経路に着目したiPS細胞における高レベル複製ストレスの原因解明
阐明 iPS 细胞中高水平复制应激的原因,重点关注范可尼贫血途径
  • 批准号:
    23K14452
  • 财政年份:
    2023
  • 资助金额:
    $ 58.21万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Analysis of the mechanism of hemolytic anemia in canine babesiosis and development of novel therapeutic measures
犬巴贝斯虫病溶血性贫血机制分析及新治疗措施开发
  • 批准号:
    23KJ0074
  • 财政年份:
    2023
  • 资助金额:
    $ 58.21万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Mobile phone-based screening for anemia in young children in western Kenya
基于手机的肯尼亚西部幼儿贫血筛查
  • 批准号:
    10752968
  • 财政年份:
    2023
  • 资助金额:
    $ 58.21万
  • 项目类别:
Brain blood flow, oxygenation, and cognition in adult onset iron deficiency anemia
成人缺铁性贫血的脑血流量、氧合和认知
  • 批准号:
    10735765
  • 财政年份:
    2023
  • 资助金额:
    $ 58.21万
  • 项目类别:
Chromatin State Alterations in Fanconi Anemia Hematologic Disease and Bone Marrow Failure
范可尼贫血血液疾病和骨髓衰竭中的染色质状态改变
  • 批准号:
    10735366
  • 财政年份:
    2023
  • 资助金额:
    $ 58.21万
  • 项目类别:
Accuracy and Feasibility of Non-Invasive Anemia Screening Assistant (ASIST) Device in Resource-Limited Settings
资源有限环境中非侵入性贫血筛查辅助 (ASIST) 设备的准确性和可行性
  • 批准号:
    10575222
  • 财政年份:
    2023
  • 资助金额:
    $ 58.21万
  • 项目类别:
Liver-Gut Axis in Neonatal Anemia and Its Role in RBC Transfusion Associated Gut Injury
新生儿贫血中的肝肠轴及其在红细胞输注相关肠道损伤中的作用
  • 批准号:
    10583807
  • 财政年份:
    2023
  • 资助金额:
    $ 58.21万
  • 项目类别:
A Sample-to-Answer Point-of-Care Diagnostic for Recently Transfused Sickle Cell Anemia Patients in Low Resource Settings
针对资源匮乏地区最近输血的镰状细胞性贫血患者的从样本到答案的护理点诊断
  • 批准号:
    10564553
  • 财政年份:
    2023
  • 资助金额:
    $ 58.21万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了